The effect of the proteolytic cleavage of plasminogen activator inhibitor type 1 (PAI-1) by human neutrophil elastase (HNE) on fibrinolysis was investigated. HNE cleaved active PAL1 and produced low molecular weight forms of inactive PAI-1, as previously reported. Latent PAL1 was resistant to HNE treatment. Vitronectin (VN) partially protected the cleavage. NH,-terminal sequence analysis indicated that the cleavage site was Va1355-Ser356 (P4-P3). The effects of PAI-1 cleavage by HNE on clot lysis was studied in a purified system. Clot lysis time without PAI-1 was 20.0 & 5.0 minutes HE CONVERSION OF plasminogen to plasmin is central to the fibrinolytic mechanism, which is achieved by plasminogen activators (PAS).'
cells was reported by Levin et al,' although its physiologic and clinical relevance has not been elucidated. HNE, a 30-kD serine protease, is able to degrade collagen, elastin, and proteoglycans" and has been implicated in tissue destruction and reconstruction occurring in various pathologic conditions."." HNE has been believed to enhance fibrinolysis by processing factors involved in fibrinolysis so as to enhance either plasminogen activation or digestion of fibrin. One is the proteolytic cleavage of the N-terminus region of Gluplasminogen forming a more susceptible form of Lys-plasminogen or Val-plasminogen." Another mechanism is a direct digestion of fibrin by HNE.I4 The amounts of HNE required to digest fibrin or Glu-plasminogen to enhance fibrinolysis effectively, however, are rather high, and the physiologic relevance of such mechanisms is still controversial. Recently a novel mechanism of HNE-induced enhancement of fibrinolysis, a proteolytic cleavage and inactivation by a lower concentration of HNE of a2-antiplasmin, a main inhibitor of plasmin and a member of SERPIN superfamily, was reported.Is Because both a2-AP and PAI-l belong to SER-PIN and play particular roles in the regulation of fibrinolysis, we believe it important to investigate the physiologic role of PAL1 cleavage by HNE. Therefore, the objective of the present study, is to examine the potential effect of the PAI-1 cleavage by HNE on clot lysis, and to elucidate a possible mechanism of HNE-induced enhancement of fibrinolysis.
PROTEOLYTIC INACTIVATION OF PAL1 BY ELASTASE 1057
Cross (Osaka, Japan). Two-chain P A was kindly provided by Sumitom0 Pharmaceutical CO (Osaka, Japan). Human neutrophil elastase was purchased from Athens Research and Technology, Inc (Athens, GA). The two-chain uPA substrate S-2444 (L-Pyroglutamyl-glycyl-L-arginine-pnitroanilide) was purchased from KabiVitrum (Stockholm, Sweden). Human vitronectin (W) was purchased from Promega (Madison, W). A rabbit polyclonal antisera raised against rpPAI-1".'6 was kindly provided by Dr Tor Ny (Umei University). Goat-antirabbit IgG horseradish peroxidase conjugate was purchased from Bio-Rad Laboratories (Richmond, CA).
Sodium abdecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE was performed according to Laemmli" and protein bands were stained either by coomassie brilliant blue or by immunoblot analysis using a rabbit polyclonal antisera against PAI-1 after transblotting onto a nitrocellulose membrane. Nonstained and prestained low molecular weight standards and nitrocellulose membrane were purchased from Bio-Rad Laboratories.
Analyses of the proteolytic action of HNE on active and latent @AI-I. rpPAI-l (0.36 pmoVL) was incubated with HNE (17 nmoYL) for various intervals at 37T, and the reaction was stopped by the addition of the sample buffer for SDS-PAGE. The samples were then subjected to 10% SDS-PAGE. The latent form of rpPAI-1 was obtained by incubation of active rpPAI-1 at 37°C for 48 hours, and its specific activity was not detectable after the treatment. The latent form of rpPAI-l was also treated by HNE, as mentioned above, and the proteolytic action of HNE was analyzed by SDS-PAGE.
Analyses of the cleavage and inactivation of rpPAI-I by HNE. To study the effect of HNE on the inhibitory activity, 0.1 pmoVL of purified rpPAI-l was incubated either in the presence or absence of 0.4 pmoVL of VN with various concentrations of HNE (0, 2.5, 5, 10, 21, 41, and 83 nmoYL) for 10 minutes or with 10 nmoVL HNE for various time intervals (0, 3,5, 10,30,60, and 120 minutes) at 37°C. The reaction mixtures were then diluted two times with 50 mmoVL Tris-HC1 pH 7.4 containing 100 mmol/L NaCl and were subjected for the activity assay. The residual inhibitory activity toward uPA was expressed as a percentage of nontreated rpPAI-l activity.
Measurement of clot lysis. For the clot lysis assay, 96-well microtiter plates were used. A total of 2 pmol/L fibrinogen, l pmol/L Glu-plasminogen, 0.2 nmoVL tPA, 68 nmoVL rpPAI-l, and various concentrations of HNE (0, 0.63, 1.25, 2.5, 5, 10, 20, 40, and 80 nmoVL) were added to individual wells, and the clot formation was initiated by 1 U/mL of human thrombin. Absorbance at 405 nm in each well was measured every 10 minutes for up to 6 hours, using an automatic microtiter plate reader (Plate Analyzer ETY-300 TOYO, Tokyo, Japan). The absorbance data were plotted against time, and the clot lysis time was obtained by an average of the maximum and the minimum absorbance values.z1.22 The data were expressed by mean 2 standard deviation. to the euglobulin fraction of plasma and was treated by various concentrations of HNE (0, 66, 132, 198, and 264 nmoYL) for 30 minutes at 37°C. The reaction was stopped by the addition of the sample buffer for SDS-PAGE. The protein bands were separated by SDS-PAGE and were electroblotted onto nitrocellulose membranes. Specific PAI-l bands were detected using a rabbit polyclonal antisera against PAI-1 followed by goat-antirabbit IgG horseradish peroxidase conjugate. Edman degradation. Automatic amino acid sequence analyses were performed by using the Applied Biosystems protein sequencer (model 476A Applied Biosystems, Foster City, CA), according to established p r o c e d~r e s .~~ For N-terminal sequence analysis, rpPAI-1 (3.8 pmoYL) was incubated with 17 nmoVL HNE in a final volume of 100 pL for 60 minutes at 37°C. The reaction was stopped and the sample (57 pmol of rpPAI-l) was loaded onto a polybrenetreated glass-fiber filter. All data were acquired using a Macintosh IIsi workstation that was interfaced to the protein sequencer via an Applied Biosystems AID Converter. Data analysis was performed using an Applied Biosystems Model 610A data analysis program.
RESULTS
The proteolytic action of HNE on active and latent rpPAI-1. As illustrated in Fig 1, rpPAI-l was proteolytically cleaved by a catalytic concentration of HNE resulting in the formation of a lower molecular weight form (40 kD) in a time-dependent manner. Because the molecular weight of the lower band is similar to the proteolytically cleaved form of rpPAI-l by PAS at its reactive site,' the cleavage site in rpPAI-l by HNE seems to be close to its reactive center. When latent rpPAI-1 was incubated with HNE, rpPAI-1 was not cleaved by HNE and remained as an intact form even after a 2-hour incubation (data not shown). Such different behaviors of HNE on different forms of rpPAI-l suggest that the cleavage site of active rpPAI-l by HNE exists in the reactive center loop, which is hidden in the latent form of rpPAI-l Mod$cation of the activity of rpPAI-l a f e r the cleavage by HNE. After incubation of 0.1 pmoVL active rpPAI-l either in the presence or absence of 0.4 prnoVL of VN with HNE for various intervals, residual activity of rpPAI-l was measured. Inhibitory activity decreased both in the presence and absence of VN with the time course (Fig 2) . Approximately 100% of the activity in the absence of VN and 80% in the presence of VN were lost after a 30-minute incubation. Inactivation of rpPAI-1 was also in a dose-dependent manner of HNE at the concentration range from 0 to 83 nmol/L (Fig  3) . Incubation of rpPAI-l with 10 nmoyL of HNE resulted in a loss of approximately 56% of rpPAI-l activity in the absence of VN and 38% in the presence of VN within 10 minutes at 37°C. VN seems not only to stabilize active PAI-1 but to tend to protect active PAI-1 from HNE digestion, although its protective potential is not strong.
Effect of HNE on$brin clot lysis time in a purzped system. To evaluate the relevance of rpPAI-l cleavage by HNE on fibrin clot lysis initiated by tPA, fibrin clot was formed in the presence of rpPAI-l and different concentrations of HNE, and the clot lysis time was measured. Clot lysis time was 20.0 2 5.0 minutes in the absence of rpPAI-l and was prolonged to 86.7 % 2.9 minutes when rpPAI-l was involved in the clot (mean +-SD, n = 3). Clot lysis time was shortened when increasing amounts of HNE were involved in the clot together with rpPAI-l (Fig 4) . In the presence of HNE at the highest concentrations, clot lysis time showed essentially the same as those obtained in the absence of rpPAI-l. Because HNE is able to degrade many fibrinolytic factors and enhance fibrin clot lysis, we conducted a similar fibrin clot lysis assay in the absence of rpPAI-l. Although the same range of the concentration of HNE was used, the clot lysis time was not shortened. Therefore, proteolytic action of HNE on fibrinolytic factors other than PAI-1 is not responsible for the shortening of fibrin clot lysis observed in the presence of PAI-I under the experimental condition used in the present study.
Effecr of HNE on ECLT. To investigate the effect of PAL1 cleavage by HNE on fibrinolysis under physiologic conditions, we employed ECLT. which is known to be wellcontrolled by PAI-1. HNE shortened ECLT by a concentration-dependent manner (Fig 5 ) . Because ECLT was shown to correlate well to active PAI-I concentration and to be regulated by PAI-I, the shortening was likely induced by a cleavage and inactivation of PAI-I in the euglobulin fraction by HNE. To confirm this, we used western blot analysis and investigated whether active rpPAI-l could be cleaved by HNE in the euglobulin fraction of plasma. Supplemented rpPAI-l was shown to be cleaved to smaller forms in the euglobulin fraction by HNE (Fig 6) .
Amino acid sequence around the cleavage site in rpPAIl bv HNE. Automated sequence analysis of an unfractionated HNE digest of rpPAI-l gave two residues in about 1 :0.8 c .
- ratio for the first 15 steps ( Table 1) . One sequence was consistent with the N-terminal sequence in rpPAI-l (repetitive yield: 94.1%), and the other was the new sequence of Ser-Ala-Arg-Met-Ala (repetitive yield: 94.3%). This sequence originates from the C-terminal position of the intact PAI-I molecule and corresponds to amino acid residues 356-360. The cleavage site of PAI-I by HNE appears to be between the residues Va1355-Ser356, which corresponds to three amino acids upstream (P4-P3) to its reactive site (Pl-PI').
DISCUSSION
In the present study, we have shown that active rpPAI-I was cleaved and inactivated by HNE and that fibrin clot lysis was augmented because of a higher expression of tPA activity induced most likely by a cleavage of PAI-I by HNE.
The major inhibitor of fibrinolysis, PAI-I, is of vital importance for the homeostatic balance in the fibrinolytic system. Hereditary or acquired PAI-I deficiency was shown to be associated with an increased bleeding risk.*'.*' The cleavage and inactivation of PAI-I by HNE, therefore, are of special medical interest to express higher fibrinolytic activity. PAL1 belongs to the SERPIN superfamily, and its reactive center is located at Arg358 and Met359 (PI and PI').' 
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Its proteolytic cleavage by PAS after a modification of its tertiary structure by SDS treatment has been reported.* The cleavage of PAI-1 by HNE was first shown by Levin et al.9 Considering the fact that the relative molecular mass of the cleaved form is similar to that cleaved at its reactive site by PAS' and that rpPAI-l lost its specific activity after cleavage by HNE, HNE most likely cleaved rpPAI-l in its reactive center loop. Another fact of the failure to cleave the latent form of rpPAI-l by HNE also supports this assumption as a part of the reactive site loop of the latent form of PAL1 is buried in the molecule as shown by radiograph crystallogr a~h y . '~ HNE is a broad spectrum protease and preferentially cleaves as in the P1 position valine or alanine residues." Among large numbers of valine and alanine in the reactive center loop, Val355 (P4), Ala357 (P2), or Ala360 (P2') could be probable candidates. The amino acid sequence analyses of the cleaved rpPAI-l by HNE showed that HNE cleaved rpPAI-l at the Val355-Ser356 peptide bond, which corresponds to P4-P3 in intact PAI-1. The cleavage of PAL1 by HNE, therefore, resulted in the release of C-terminal peptide, which contains its reactive site, and PAI-1 naturally lost its specific activity.
Indeed, as shown in the present report, isolated active rpPAI-l is readily proteolytically cleaved by HNE, thereby loosing its inhibitory activity. The question of the clinical relevance of this phenomenon became substantial. Spontaneous lysis of either plasma2' or euglobulin clot" is reported to be dependent on PAI-1 content in the clot. Not only in fluid phase, PAI-l is shown to bind to fibrin and inactivate plasminogen activators on the surface of the fibrin2' resulting in the prolongation of clot lysis. To our surprise, when a clot was formed in the presence of tPA, rpPAI-l, and elastase, rpPAI-1 was inactivated very easily by HNE and higher tPA activity was obtained. Not only in a purified system, but in the euglobulin fraction of plasma, PAI-1 was cleaved by HNE, and ECLT was shortened after HNE treatment. PAI-l is shown to inactivate single-chain tPA with a second order rate constant of 3.5 X 107/mol/L/s and two chain tPA with a faster rate, by forming high molecular weight complexes.'* Therefore, the cleavage and inactivation of rpPAI-1 by HNE, must also be very rapid to obtain free tPA. The mechanism by which SERPIN interacts with its target serine protease is not fully understood, and the reversibility of the complex formation is still controversial. Amino terminal sequence analysis of plasminogen activators and PAI-l has shown that the peptide bond between the P1 and P1' residues is cleaved,30 suggesting P1 residue and serine residue of the target protease are covalently bound. By using complexes between a2-antiplasmin and trypsin or chymotrypsin, the dissociation of the complex into both active enzyme and intact inhibitor in the presence of a2-macroglobulin was shown." Reversible binding was also shown by a kinetic study applying a slow binding kinetics theory.32 Progressive dissociation of preformed tPA/PAI-1 complex in consequence of the decrease of free PAI-1 concentration by the cleavage of PAI-l by HNE and the release of free tPA from the complex could be another possible mechanism to express higher tPA activity. Because plasminogen activation activity is fine tuned by the balance of the concentrations between tPA and PAL1 in plasma:'.22 its slight modification could largely affect the entire fibrinolytic activity. The shortening of the fibrin clot lysis and ECLT by catalytic amounts of HNE clearly suggests that the cleavage and inactivation of PAL1 by HNE is physiologically relevant to express higher fibrinolytic activity in vivo.
Some investigations have been performed to provide some insights into participation of physiologic fibrinolysis caused by HNE, as leukocytes are known to accumulate extensively in thrombi, resulting in the release of leukocyte elastase during blood c~a g u l a t i o n .~~.~~ Normal plasma concentration of HNE is reported to be less than 1 nmol/L. When whole blood was coagulated at 37"C, however, serum HNE levels increased in the range from 14 to 23 nmoVL at which concentration PAI-1 is readily cleaved in a purified system.35 Because of the fact that larger amounts of HNE were required to shorten ECLT and that HNE is readily inactivated by a1-antitrypsin in plasma, HNE may barely cleave PAL1 in plasma milieu under physiologic conditions. Several lines of data, however, suggest that the cleavage of PAI-1 by HNE occurs under certain pathologic conditions. Acute promyelocytic leukemia (APL) is known to show a particular coagulopathy, of which biologic features resemble those of disseminated intravascular coagulation (DIC). Although an involvement of leukocyte protease is highly suggested, the precise mechanism to induce hemorrhage is not yet fully understood. Recently, lower plasma PAL 1 activity despite their higher PAI-l antigen level was reported in APL which has a high elastasehl-antitrypsin complex level (about 15-fold).36 Sakata et a126 directly showed a lower molecular weight form of PAI-1 in the plasma of an APL patient who had hemorrhagic symptoms. The cleavage and inactivation of PAL1 by HNE released from leukocytes seem, at least in part, to be responsible for expressing higher fibrinolytic activity that results in the hemorrhagic features in APL. Besides APL, under the conditions when large amounts of HNE are released from neutrophils, such as endotoxin hock,'^ septicemia,38 adult respiratory distress ~yndrome,'~ hemodialysis,'"' and cardiovascular surgery:' such mechanisms to enhance fibrinolytic activity may also take place.
HNE-induced enhancement of fibrinolysis has been suggested for a long time. Direct proteolysis of fibrin and the conversion of the native form of Glu-plasminogen to a more susceptible form of plasminogen were suggested as main pathways for HNE to enhance fibrinolysis. In the present study, however, no significant shortening of fibrin clot lysis was observed in the absence of rpPAI-l, and the relevance of these mechanisms became questionable. Recently, the cleavage and inactivation of a2-antiplasmin, a main inhibitor for plasmin and a member of SEWIN superfamily, was suggested as another mechanism to enhance fibrin~lysis.'~ Taking our data shown in the present study into account, the cleavage and inactivation of relevant serine protease inhibitors involved in the fibrinolysis by HNE, could be an important mechanism to express higher fibrinolytic activity resulting in the enhancement of fibrinolysis.
